Operational Costs Compared: SG&A Analysis of Genmab A/S and Axsome Therapeutics, Inc.

SG&A Expenses: A Tale of Two Biotechs

In the competitive world of biotechnology, operational efficiency is key. This analysis compares the Selling, General, and Administrative (SG&A) expenses of Genmab A/S and Axsome Therapeutics, Inc. over the past decade. Since 2014, Genmab A/S has consistently outpaced Axsome in SG&A spending, reflecting its larger scale and broader market reach. By 2023, Genmab's SG&A expenses surged to nearly 3.3 billion, a staggering 10-fold increase from 2014. In contrast, Axsome's expenses grew from a modest 1.4 million to 323 million, marking a significant expansion as the company scales its operations. This trend highlights the differing growth trajectories and strategic priorities of these two biotech firms. As Genmab continues to invest heavily in its operations, Axsome's rapid increase in SG&A expenses signals its aggressive push to capture market share. Understanding these dynamics offers valuable insights into the operational strategies of leading biotech companies.